Cargando…
Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
We started a single-arm, phase II, open-label, prospective clinical trial using steroids-ruxolitinib as the first-line therapy for intermediate- to high-risk aGVHD (NCT04397367). Here, we report the association of a biomarker panel (sST2, REG3α, sTNFR1, IL-6 and IL-8) with responses to GVHD therapy....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610441/ https://www.ncbi.nlm.nih.gov/pubmed/34816294 http://dx.doi.org/10.1007/s00277-021-04727-1 |